Show simple item record

dc.contributor.authorWallis, SC
dc.contributor.authorMullany, DV
dc.contributor.authorLipman, J
dc.contributor.authorRickard, CM
dc.contributor.authorDaley, PJ
dc.date.accessioned2007-05-10
dc.date.accessioned2014-06-19T22:44:22Z
dc.date.accessioned2017-03-02T00:11:17Z
dc.date.available2017-03-02T00:11:17Z
dc.date.issued2001
dc.date.modified2014-06-19T22:44:22Z
dc.identifier.issn0342-4642
dc.identifier.doi10.1007/s001340100857
dc.identifier.urihttp://hdl.handle.net/10072/60697
dc.description.abstractObjectives: To investigate the pharmacokinetics of intravenous ciprofloxacin 200 mg every 8 h in critically ill patients on continuous veno-venous haemodiafiltration (CVVHDF), one form of continuous renal replacement therapy (CRRT). Design and setting: Open, prospective clinical study in a multidisciplinary, intensive care unit in a university-affiliated tertiary referral hospital. Patients: Six critically ill patients with acute renal failure on CVVHDF. Interventions: Timed blood and ultrafiltrate samples were collected to allow pharmacokinetics and clearances to be calculated of initial and subsequent doses of 200 mg intravenous ciprofloxacin. CVVHD was performed with 1 l/h of dialysate and 2 l/h of predilution filtration solution, producing 3 l/h of dialysis effluent. The blood was pumped at 200 ml/min using a Gambro BMM-10 blood pump through a Hospal AN69HF haemofilter. Measurements and results: Ten pharmacokinetic profiles were measured. The CVVHDF displayed a urea clearance of 42±3 ml/min, and removed ciprofloxacin with a clearance of 37±7 ml/min. This rate was 2–2.5 greater than previously published for ciprofloxacin in other forms of CRRT. On average the CVVHDF was responsible for clearing a fifth of all ciprofloxacin eliminated (21±10%). The total body clearance of ciprofloxacin was 12.2±4.3 l/h. The trough concentration following the initial dose was 0.7±0.3 mg/l. The area under the plasma concentration time curves over a 24-h period ranged from 21 to 55 mg·h l–1. Conclusions: Intravenous ciprofloxacin 600 mg/day in critically ill patients using this form of CRRT produced adequate plasma levels for many resistant microbes found in intensive care units.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherSpringer Berlin
dc.publisher.placeHeidelberg
dc.relation.ispartofpagefrom665
dc.relation.ispartofpageto672
dc.relation.ispartofissue4
dc.relation.ispartofjournalIntensive Care Medicine
dc.relation.ispartofvolume27
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchPublic Health and Health Services
dc.subject.fieldofresearchcode1103
dc.subject.fieldofresearchcode1117
dc.titlePharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration.
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codec1x
gro.facultyGriffith Health Faculty
gro.hasfulltextNo Full Text
gro.griffith.authorRickard, Claire


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record